Related Experiment Videos
[Immunomodulating basic therapy of rheumatoid arthritis using ciamexone]
C Baerwald1, K M Goebel, A Krause
1Zentrum Innere Medizin der Universität Marburg/Lahn.
Schweizerische Medizinische Wochenschrift
|December 9, 1989
Summary
Ciamexone effectively reduced clinical and biochemical scores in rheumatoid arthritis patients over six months. The treatment also decreased activated T-lymphocytes but showed potential toxicity.
Area of Science:
- Immunology
- Pharmacology
Context:
- Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation.
- Ciamexone, a 2-cyanoaziridine derivative, demonstrated in vitro selective inhibition of autoreactive lymphocytes in animal models.
Purpose:
- To evaluate the clinical efficacy and safety of ciamexone in patients with active rheumatoid arthritis (RA).
- To assess ciamexone's impact on systemic inflammatory markers and T-lymphocyte subsets in RA patients.
Summary:
- A pilot study treated 10 RA patients with ciamexone for 6 months.
- Significant reductions in clinical and biochemical disease scores were observed.
- A decrease in activated T-lymphocytes and minor side effects (rash, hepatotoxicity, diarrhea) were noted.
Impact:
- Ciamexone demonstrates clinical efficacy in treating active rheumatoid arthritis.
- The study highlights ciamexone's potential immunomodulatory effects on T-lymphocytes.
- Findings suggest ciamexone's potential toxicity warrants further investigation.